Brief: Annexin Announces Success In Co's Cancer Initiative

Annexin Pharmaceuticals AB (publ)

29/09/2023 08:00

Sept 29 (Reuters) - Annexin Pharmaceuticals AB (publ)
 ANNX.ST :
    * ANNEXIN ANNOUNCES SUCCESS IN THE COMPANY'S CANCER
INITIATIVE
    * IMPORTANT PROGRESS IN COMPANY'S PRECLINICAL CANCER
RESEARCH
WHERE DRUG CANDIDATE ANXV HAS SHOWN PROMISING RESULTS AS A
TRANSPORTER OF CHEMOTHERAPY DRUGS TO KILL CANCER CELLS
    * HAS SUCCESSFULLY PRODUCED A SO-CALLED CONJUGATE WHERE DRUG
CANDIDATE ANXV IS CHEMICALLY BOUND TO A CHEMOTHERAPY AGENT AND
TOGETHER FORMS A NEW COMPOSITE MOLECULE
    * IN CELL SYSTEMS OUTSIDE BODY, THIS ANXV CONJUGATE HAS BEEN
SHOWN
TO KILL A TYPE OF CANCER CELL TAKEN FROM A PERSON WITH
TRIPLE-NEGATIVE BREAST CANCER

Source text for Eikon:  ID:nWkr9nlLpb 
Further company coverage:  ANNX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))